BIF002
/ City of Hope
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
November 03, 2023
IL1RAP-Specific T Cell Engager (TCE) Antibody Efficiently Depletes Acute Myeloid Leukemia (AML) Leukemic Stem Cells (LSCs)
(ASH 2023)
- "In summary, we provide evidence of the subnanomolar potency and efficacy of BIF002, a novel anti-IL1RAP/CD3 TCE, in eliminating AML blasts, including LSCs. BIF002 is currently undergoing IND-enabling studies."
IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • CD34 • IL1RAP
August 15, 2024
IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells.
(PubMed, J Hematol Oncol)
- "The novel anti-IL1RAP/CD3 TCE, BIF002, eradicates LSCs and significantly prolongs survival of AML xenografts, representing a promising, novel treatment for AML."
Journal • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • CD34 • IL1RAP • SDC1
December 11, 2023
City of Hope Scientists Present Promising New Research at American Society of Hematology Annual Meeting
(Businesswire)
- "To find a therapeutic workaround for acute myeloid leukemia (AML), City of Hope researchers created a mouse-human chimeric bispecific T cell engager called BiF002 that incorporates a human form of immunoglobulin G....In three different mouse models, BIF002 significantly impeded disease progression and prolonged the lives of mice with human AML, all without causing side effects,..."
Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Oncology
1 to 3
Of
3
Go to page
1